profit from every $100 of sales.
$0$100
Treace Medical Concepts
$5.06+3.69% today
+50.6% in 1 year
1-year low $1.201-year high $5.06
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Treace Medical Concepts sold, what it kept, and what it did with the cash.
Sales went from $142 million in 2022 to $213 million in 2025, with -$59.0 million of profit last year.
SalesProfit
Treace Medical Concepts vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Treace Medical Concepts | No profit yet | ||
 Boston Scientific | 22.6× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.8× · Expensive | ||
 Zimmer Biomet Holdings | 28.8× · Fair price |
AI analysis
An AI analyst reads Treace Medical Concepts's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 142 | 187 | 209 | 213 | |
| 116 | 152 | 168 | 170 | |
| -35 | -51 | -56 | -54 | |
| -36 | -39 | -42 | -43 | |
| -43 | -50 | -56 | -59 | |
| -0.77 | -0.81 | -0.90 | -0.93 | |
| 82.0% | 81.2% | 80.4% | 79.8% | |
| -24.6% | -27.5% | -26.6% | -25.5% | |
| -30.2% | -26.5% | -26.6% | -27.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 159 | 252 | 217 | 191 |
| Cash | 19 | 13 | 11 | 11 |
| Total debt | 69 | 70 | 70 | 72 |
| Total liabilities | 98 | 114 | 104 | 103 |
| 61 | 138 | 113 | 87 | |
| 55 | 61 | 62 | 63 | |
| -23.5% | -16.8% | -21.8% | -26.6% | |
| -70.7% | -35.9% | -49.4% | -67.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -31 | -35 | -37 | -16 | |
| 15 | 11 | 12 | 14 | |
| -45 | -46 | -49 | -29 | |
| Dividends paid | – | 0 | 0 | 0 |
| – | – | – | – | |
| 8 | 17 | 31 | 34 |
Valuation
- –
- –
- –
- 2.0×
- 1.6×
- –
- –
- -8.9%
- -17.8%
- 0.0%
Profitability
- 79.8%
- -25.5%
- -27.7%
- -22.7%
- -37.3%
- -32.5%
- -69.5%
- -33.2%
- -37.3%
- 9.3%
Growth
- +14.5%
- –
- +39.5%
- –
- +4.0%
Financial health
- –
- 0.18
- 7.4%
- -10.0×
- 3.58
- 2.53
- 1.13
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 12%of 958
Bottom 10%of 889
Top 39%of 890
Bottom 11%of 987
What analysts expect
- Average price target
- $3.00
- Range
- $3.00 – $3.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 8, 2026 | -0.28 | -0.31 | +9.7% |
| Feb 27, 2026 | -0.12 | -0.15 | +21.0% |
| Nov 6, 2025 | -0.26 | -0.28 | +7.1% |
| Aug 7, 2025 | -0.28 | -0.29 | +3.4% |
| May 8, 2025 | -0.25 | -0.31 | +19.4% |
| Feb 27, 2025 | -0.01 | -0.04 | +75.0% |
| Nov 5, 2024 | -0.25 | -0.27 | +7.4% |
| Aug 6, 2024 | -0.34 | -0.29 | −17.2% |
News
Treace outlines $206M-$210M 2026 revenue range while targeting $700M TAM expansionSeeking Alpha · Nov 7, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
54No pass
Philip Fisher
40No pass
Peter Lynch
54No pass
Joel Greenblatt
2No pass
Charlie Munger
31No pass
Terry Smith
33No pass
Questions about Treace Medical Concepts
Is Treace Medical Concepts a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Treace Medical Concepts AI analysis
What does Treace Medical Concepts do?
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It is in Medical - Devices.
Does Treace Medical Concepts pay a dividend?
No. Treace Medical Concepts does not pay a dividend at the moment.
Is Treace Medical Concepts stock halal?
Yes. Treace Medical Concepts passes our halal screen: its business is permitted and its debt is 22% of its market value, under the 30% limit. How we check
How has Treace Medical Concepts stock done over the past year?
Up 50.6% over the past twelve months, to $5.06. It traded between $1.20 and $5.06, close to its high.
Who are Treace Medical Concepts's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Treace Medical Concepts's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.